IDegLira HIGH Trial

Therapuetic Areas:Endocrinology
Age Range:18 - 80
Start Date:January 15, 2019
End Date:December 2021
Contact:Rodolfo Galindo, MD

Use our guide to learn which trials are right for you!

A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira Versus Basal Bolus in Patients With Poorly Controlled Type 2 Diabetes

Basal-bolus insulin therapy is recommended for patients with poorly controlled type 2
diabetes (T2D) and HbA1c >9%. However, basal-bolus insulin is labor intensive and associated
with increased risk of hypoglycemia, glycemic variability, weight gain and poor compliance.
Thus, there is a critical need for a simpler treatment regimen that could overcome these
limitations. IDegLira, a fixed-ratio combination (FRC) therapy consisting of insulin degludec
and liraglutide, is an attractive option for this population given its proven benefits on
glycemic control, weight and compliance. This study aims to show that a simpler regimen using
a novel FRC agent (IDegLira) can improve glycemic control, decrease hypoglycemia, reduce the
burden of diabetes care, and improve satisfaction/adherence in patients with poorly
controlled T2D with HbA1c between ≥ 9-12%. This open-label, treat-to- target, two-arm
parallel, controlled trial will randomize participants with T2D and HbA1c ≥ 9%, treated with
oral anti-diabetic agents and/or basal insulin therapy to lDegLira or basal-bolus insulin for
26 weeks.

Extensive literature has shown that persistent hyperglycemia is associated with short- and
long-term complications. Sustained hyperglycemia, also known as glucotoxicity, leads to
progressive loss of beta-cell function and is considered a key pathophysiological process in
the development of type 2 diabetes (T2D). Patients with severe hyperglycemia may respond
poorly to oral anti-diabetic agents (OAD) alone initially and frequently require insulin to
achieve glycemic targets. Current guidelines recommend to initiate therapy with basal insulin
and progressively step up to basal-bolus insulin in patients with high HbA1c >9%,
particularly if symptomatic or with catabolic symptoms.

A basal-bolus insulin regimen increases the risk of hypoglycemia, weight gain and glycemic
variability, which are limiting factors in achieving glycemic targets. A basal-bolus insulin
regimen is also labor intensive and often requires multiple daily injections, further
increasing the burden of diabetes care and decreasing patient adherence. In contrast,
simplified treatment plans may improve adherence, leading to glycemic targets achievement.
Thus, there is a critical need for simpler regimens that could overcome clinical inertia,
improve patient adherence, and decrease glycemic variability in patients with poorly
controlled type 2 diabetes. This prospective randomized control trial will compare IDegLira
to basal-bolus insulin regimen in achieving glycemic control, while reducing hypoglycemia,
glycemic variability, and weight gain in patients with uncontrolled T2D and HbA1c ≥9%.

Inclusion Criteria:

- Type 2 diabetes, diagnosed for ≥ 6 months

- HBA1c ≥ 9% - 12%

- Previously treated with oral antidiabetic agents, including metformin, sulfonylurea,
repaglinide/nateglinide, pioglitazone, dipeptidyl peptidase-4 (DPP4), inhibitors,
SGLT2 inhibitors, (monotherapy + basal insulin) or in combination therapy (2-3
agents), and/or on basal insulin (neutral protamine hagedorn (NPH), detemir or
glargine U100) at a total daily dose (TDD) 20-50 units (stable doses of metformin and
basal insulin for at least 90 days, defined as up to ±10% variability)

- Body mass index (BMI) ≥ 25 Kg/m2 and ≤ 40 Kg/m2

Exclusion Criteria:

- Subjects with type 1 diabetes or latent autoimmune diabetes of adults (LADA) (positive
glutamic acid decarboxylase (GAD-65) antibody and/or ketones)

- Subjects with a BG > 400 mg/dL during the screening visit and laboratory evidence of
diabetic ketoacidosis

- Previous treatment with glucagon-like peptide-1 (GLP-1) agonists (during prior 3

- Previous treatment with basal-bolus insulin or mixed insulin (within prior 3 months)

- Recurrent severe hypoglycemia or known hypoglycemia unawareness.

- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia

- Patients with acute or chronic pancreatitis, pancreatic cancer

- Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage
liver disease) or significantly impaired renal function (GFR < 30 ml/min).

- Treatment with oral or injectable corticosteroid (equivalent or higher than prednisone
5 mg/day), parenteral nutrition and immunosuppressive treatment.

- Mental condition rendering the subject unable to understand the nature, scope, and
possible consequences of the study

- Hypersensitivity to study drugs

- Participating in another investigational drug trial

- The receipt of any investigational drug (within 3 months) prior to this trial.

- Previously randomized in this trial

- Heart Failure New York Heart Association (NYHA) class 4 or uncontrolled hypertension
(blood pressure > 180/110 mmHg)

- Female subjects who are pregnant or breast-feeding at time of enrollment into the

- Females of childbearing potential who are not using adequate contraceptive methods (as
required by local law or practice)

- Known or suspected allergy to trial medications (degludec, liraglutide, aspart),
excipients, or related products.

- Subjects could be excluded based on PI's discretion

- Unable to comply with trial protocol, and/or at investigator discretion

- Patients receiving treatment for active diabetic retinopathy or with proliferative
We found this trial at
Atlanta, Georgia 30322
Phone: 404-251-8961
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30303
Phone: 404-251-8961
Atlanta, GA
Click here to add this to my saved trials